Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment. (7th February 2022)

• Record Type: Journal Article
• Authors: Mizukami, Takuro; Hamaji, Koki; Onuki, Risa; Yokomizo, Ayako; Nagashima, Yoshie; Takeda, Hiroyuki; Umemoto, Kumiko; Doi, Ayako; Arai, Hiroyuki; Hirakawa, Mami; Horie, Yoshiki; Izawa, Naoki; Ogura, Takashi; Tsuda, Takashi; Sunakawa, Yu; Shibata, Michi; Tanaka, Tsuneaki; Mikami, Shinya; Nakajima, Takako Eguchi
• Is Part Of: Nutrition and cancer. Volume 74:Number 2(2022)
• Page Start: 539
• Page End: 545
• Publication Date: 2022-02-07
• Subjects: Cancer -- Periodicals; Nutrition -- Periodicals; Cancer; Nutrition; Periodicals; 616.9940654
• DOI: 10.1080/01635581.2021.1902542
• Languages: English
• ISSNs: 0163-5581

Abstract

Abstract: Limited information is available regarding the impact of body weight loss (BWL) in patients with advanced gastric cancer (AGC) who receive second-line chemotherapy. We retrospectively reviewed data for consecutive AGC patients who received second-line treatment with taxane-based chemotherapy at our institution between January 2014 and September 2018. We calculated variables, including percent BWL per month during chemotherapy (%BWL/m), and analyzed the correlations between BWL and other clinicopathological parameters with survival. Forty-four AGC patients were registered (median age, 67.5 years; females, n = 16 [36.3%]; severe ascites, n = 12 [27.3%]). The median overall survival was significantly shorter among patients with a %BWL/m of 1% or more, compared with patients with less weight loss (6.3 mo, vs. 12.3 mo, P = 0.038). The %BWL/m (≥1% vs. <1%) was significantly correlated with survival in a univariate analysis (HR = 2.11, P = 0.04), and the survival period was shorter for patients with severe ascites (HR = 1.92; 95% CI, 0.90–3.90) and if their %BWL/m was 1% or more (HR = 2.01; 95% CI, 0.98–4.10) in a multivariate analysis. In conclusion, BWL during second-line chemotherapy was associated with a poor prognosis among patients with AGC.